Corcept Therapeutics (CORT) closed at $80.46 on November 2, 2026, down 0.8% from the previous close, on volume of 1,446,464 shares (30-day average 904,566).
Data as of November 2, 2026.
TipRanks (Mon, 2-Nov 3:55 PM ET)
Wall Street Analysts Are Bullish on Top NA Picks
TipRanks (Mon, 2-Nov 2:10 PM ET)
TipRanks (Mon, 2-Nov 2:00 PM ET)
TipRanks (Mon, 2-Nov 7:00 AM ET)
Business Wire (Tue, 27-Oct 4:05 PM ET)
Market Chameleon (Mon, 26-Oct 5:41 AM ET)
Business Wire (Mon, 26-Oct 8:00 AM ET)
Business Wire (Tue, 20-Oct 4:00 PM ET)
Globe Newswire (Fri, 9-Oct 11:55 AM ET)
Corcept Announces Planned Leadership Transition
Business Wire (Wed, 23-Sep 8:00 AM ET)
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Corcept Therapeutics trades on the NASDAQ stock market under the symbol CORT.
As of November 2, 2026, CORT stock price declined to $80.46 with 1,446,464 million shares trading.
CORT has a beta of 1.27, meaning it tends to be more sensitive to market movements. CORT has a correlation of 0.02 to the broad based SPY ETF.
CORT has a market cap of $8.70 billion. This is considered a Mid Cap stock.
Last quarter Corcept Therapeutics reported $256 million in Revenue and $.36 earnings per share. This beat revenue expectation by $37 million and exceeded earnings estimates by $.34.
In the last 3 years, CORT traded as high as $126.38 and as low as $20.84.
The top ETF exchange traded funds that CORT belongs to (by Net Assets): VTI, IJH, VB, VBK, VXF.
CORT has underperformed the market in the last year with a price return of +11.3% while the SPY ETF gained +11.7%. CORT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -32.0% and -27.0%, respectively, while the SPY returned +1.7% and -1.5%, respectively.
CORT support price is $77.98 and resistance is $84.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CORT shares will trade within this expected range on the day.
